COMPANY Biotech from the United States, Moderna said it had carried out tests on HIV vaccine. Researchers used messenger RNA technology in humans.
Moderna is working with the International AIDS Vaccine Initiative to conduct research. This Phase 1 trial is being conducted in the United States among 56 healthy adults who are HIV-negative as of Thursday January 27, 2022.
Despite four decades of research, doctors have yet to develop a vaccine to protect people from the virus that causes AIDS. However, these hopes have paid off because of mRNA technology.
READ ALSO: 3 Stages of HIV Infection Attacking the Body to Become AIDS
The goal of the vaccine currently being tested is to stimulate the production of a type of antibody called broadly neutralizing antibodies or bnAbs. These antibodies play a role against many variants of HIV. The vaccine is claimed to produce B lymphocytes which are part of the immune system to produce these antibodies.
READ ALSO: Recognize AIDS, Symptoms and Prevention
In this trial, participants are injected with an immunogen, a substance that can trigger an immune response, and then an immunogen booster will follow. These substances will be delivered with mRNA technology.
“Induction of bnAbs is widely considered the goal of HIV vaccination, and this is the first step in that process,” said Moderna and IAVI.
The immunogen used in this trial was developed by IAVI and the Scripps Research Institute, with support from the Bill & Melinda Gates Foundation, the National Institute of Allergy, Infectious Diseases of the United States and Moderna.
